Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionGw Henssler & Associates Ltd
Latest Disclosed Ownership23,930 shares
Latest Disclosed Value $ 18,488,966
Gw Henssler & Associates Ltd reports 2.09% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 15, 2026 - Gw Henssler & Associates Ltd filed a 13F-HR form disclosing ownership of 23,930 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $18,488,966 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 24,442 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -2.09% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 23,930 -512 -2.09 18,489 -2.00 0.8709
2026-02-10 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 24,442 223 0.92 18,866 38.54 0.9078
2026-01-23 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 24,219 2,737 12.74 13,617 20.75 0.6804
2025-07-25 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 21,482 1,122 5.51 11,278 -12.66 0.6024
2025-05-15 2025-03-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 20,360 2,543 14.27 12,913 -31.06 0.7406
2025-05-14 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 17,636 -181 18,540 1.0714
2025-01-24 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 17,817 -251 -1.39 18,730 -1.39 1.0736
2024-10-25 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 18,068 -477 -2.57 18,994 -2.56 1.0744
2024-08-01 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 18,545 -908 -4.67 19,491 4.10 1.1731
2024-05-07 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 19,453 -498 -2.50 18,723 6.85 1.0998
2024-01-26 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 19,951 -528 -2.58 17,523 3.97 1.1568
2023-10-24 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 20,479 -425 -2.03 16,853 12.20 1.1505
2023-08-02 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 20,904 -198 -0.94 15,020 -13.37 0.9864
2023-04-26 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 21,102 -190 -0.89 17,339 12.87 1.1518
2023-02-03 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 21,292 410 1.96 15,362 6.78 1.0787
2022-11-04 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 20,882 411 2.01 14,385 18.87 1.0767
2022-08-04 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 20,471 55 0.27 12,101 -15.13 0.8984
2022-05-09 2022-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 20,416 370 1.85 14,259 12.64 0.8661
2022-01-28 2021-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 20,046 134 0.67 12,659 5.05 0.8075
2021-11-02 2021-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 19,912 60 0.30 12,050 8.68 0.8359
2021-08-09 2021-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 19,852 490 2.53 11,088 21.03 0.7293
2021-04-28 2021-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 19,362 883 4.78 9,161 2.62 0.6551
2021-02-02 2020-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 18,479 -1,799 -8.87 8,927 -21.35 0.6820
2020-10-22 2020-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 20,278 -13,744 -40.40 11,351 -46.50 0.9625
2020-07-21 2020-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 34,022 -2,916 -7.89 21,218 17.64 1.8652
2020-04-27 2020-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 36,938 -1,018 -2.68 18,036 26.55 1.8275
2020-02-24 2019-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 37,956 1,835 5.08 14,252 42.24 1.1785
2019-11-18 2019-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 36,121 8,382 30.22 10,020 15.41 0.8921
2019-08-05 2019-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 27,739 27,739 8,682 0.7860
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.